Literature DB >> 3532906

[Cyclosporin in the treatment of bullous pemphigoid: preliminary study].

H Barthélémy, J Thivolet, F Cambazard, A Bendelac, G Mauduit, F Granier, A Frappaz.   

Abstract

Bullous pemphigoid is a typical autoimmune disease. It is classically treated with systemic corticosteroids alone or combined with immunosuppressants. Cyclosporine A (CyA), a new immunosuppressive agent with high activity in organs and bone marrow transplantation, could be expected to prove effective in this disease owing to its action on lymphocytes. Seven patients with bullous pemphigoid were treated with CyA in daily doses of 6 to 8 mg/kg bodyweight. Treatment was monitored by measurements of serum CyA, creatinine and liver enzyme levels. The effectiveness of treatment was assessed on clinical changes. The seven cases are dealt with individually, with a brief case-report for each of them. The only side-effects observed were reversible rises in serum creatinine levels and hypertrichosis in two cases; these are usual reactions to the drug. Hormonal assays were normal in two female patients. Concerning results, our patients fell into two groups. Among those treated with CyA alone there were two failures and two sustained satisfactory results. Treatment was successful in all patients treated with CyA during relapses under corticosteroid therapy, but two patients relapsed after CyA was discontinued. It is concluded that CyA is of no interest in the acute phase of bullous pemphigoid, that the long-term stability of the results obtained is doubtful and that this potentially nephrotoxic drug should be avoided or administered with extreme caution in elderly people, since their renal function may be at the limit of normality.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3532906

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  4 in total

Review 1.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  [Bullous pemphigoid: a new look at a well-known disease].

Authors:  G Balakirski; H F Merk; M Megahed
Journal:  Hautarzt       Date:  2014-12       Impact factor: 0.751

Review 3.  Management of autoimmune skin disorders in the elderly.

Authors:  Wei Jing Loo; Nigel P Burrows
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 4.  Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic review.

Authors:  Faith A P Zeng; Anna Wilson; Tabrez Sheriff; Dedee F Murrell
Journal:  JAAD Int       Date:  2022-08-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.